CordenPharma Expands Aseptic Filling and Finishing Capacity to 500 Million Injectable Units Annually

CordenPharma's Expansion of Injectable Production Capacity

CordenPharma, a prominent Contract Development and Manufacturing Organization (CDMO), is reinforcing its position in the healthcare sector through significant investments aimed at enhancing the production capacity for sterile injectable drugs. With a long-term capital investment program, CordenPharma is set to increase its filling and finishing capacity to a staggering 500 million injectable units annually. This ambitious initiative reflects the company’s commitment to meeting the growing global demand for complex medications.

Strategic Investment

On September 10, 2026, CordenPharma announced its decision to invest €80 million in a new facility and additional filling and finishing lines at its Caponago site in Milan, Italy, which is certified by the FDA and EMA. This strategic move aims to support the increasing needs of the biopharmaceutical industry for sterile injectable products, particularly in high-demand therapeutic areas such as oncology, diabetes, and infectious diseases.

The investment primarily has two key components:

1. New Manufacturing Facility: CordenPharma has acquired a new commercial building spanning 11,000 m² and 26,000 m² of adjacent land. This expansion, completed on July 28, 2026, boosts the site’s footprint by over 50%. The new facility provides a state-of-the-art environment for the development of complex injectable therapies, including peptides, lipid nanoparticles (LNP), biologics, and oligonucleotides.

2. Operational Enhancements: Over the past two years, CordenPharma has undertaken several strategic expansions within its existing Caponago facility. These include the addition of two new aseptic filling lines equipped with isolator technology, enhancing the current capabilities. This includes a combined Bausch Ströbel line suitable for both clinical and small-scale commercial use, a high-speed Syntegon line capable of producing over 500,000 pre-filled syringes daily, and an expansion of the automated secondary packaging area for pre-filled syringes and vials.

Versatile Solutions for Clients

The newly expanded facility will accommodate up to four lines for aseptic filling and finishing, four visual inspection lines, and four additional packaging lines. CordenPharma is also set to implement client-owned lines, large-scale lyophilization, and autoinjector assembly capabilities. This extensive setup ensures that clients can leverage comprehensive services from a single location, optimizing their production processes and reducing lead times.

Customers will also benefit from integrated solutions that encompass everything from active pharmaceutical ingredients to the final pharmacological product. CordenPharma’s extensive expertise covers a wide range of products, including both high-potency and conventional active ingredients, thereby supporting clients throughout the lifecycle of their injectable drugs.

Commitment to Quality and Compliance

The completion of these new lines is anticipated by mid-2027 and 2028, enhancing CordenPharma's capacity for sterile manufacturing while maintaining the highest standards of sterility assurance and regulatory compliance. Dr. Michael Quirmbach, President, and CEO of CordenPharma Group, emphasized that this strategic investment underlines the company’s commitment to bolstering its leadership in the manufacturing of complex medications. He noted, "The backing from our shareholders, Astorg, reinforces our dedication to expanding sterile injectable manufacturing at CordenPharma Caponago."

Conclusion

With this ambitious expansion, CordenPharma is well-positioned to address the rising trend in the outsourcing of sterile injectables across various therapeutic areas, thus ensuring that innovative drug manufacturers can efficiently bring vital medications to patients. As CordenPharma continues to enhance its capabilities, it remains a trusted partner for biopharmaceutical companies looking to navigate the complexities of drug development and manufacturing.

For more information about CordenPharma and its services, visit CordenPharma's website.